Clinical Trial Update: Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6 [Phase 1]

View source ↗

Summary

Phase 1, open-label, randomized study assessing the safety and pharmacokinetics of HU6 in overweight participants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overweight

Drugs mentioned

• HU6

Snippet

Sponsor: Rivus Pharmaceuticals, Inc. | Conditions: Overweight | Phase 1 | Status: COMPLETED